Stock ABPRO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Abpro Corporation

Equities

US0008501076

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Abpro Corporation entered into a term sheet to acquire Atlantic Coastal Acquisition Corp. II from a group of shareholders for approximately $770 million in a reverse merger transaction.
CI
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of Cancer Treatment Bispecific Antibody
CI
Abpro Corporation announced that it expects to receive $79.999992 million in funding
CI
Abpro Corporation Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
CI
Abpro Announces Positive Phase 1 Results Demonstrating a Favorable Safety and Pharmacokinetic Profile of ABP 300, a Neutralizing Antibody Therapeutic for the Treatment of COVID-19
CI
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
CI
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
CI
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
GL
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
CI
Abpro Corporation announced that it expects to receive $29.999984 million in funding from Abpro Bio International, Inc.
CI
Abpro and NJCTTQ Enters Into Partnership for Development of Multiple Novel Bispecific Antibodies
CI
Abpro Corporation has withdrawn its IPO in the amount of $64 million.
CI
Abpro Corporation has filed an IPO in the amount of $69 million.
CI
Abpro Seeks Acquisitions
CI
Abpro Corporation announced that it has received $9.99999 million in funding
CI
Abpro Corporation announced a financing transaction
CI
Abpro Appoints MacBeath as Chief Scientific Officer
CI
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology
CI
Abpro Announces Investment and Partnership with Essex Bio for Development of Antibody Therapeutics
CI
Abpro Corporation announced that it has received $3.5 million in funding from Essex Bio-Technology Limited
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Abpro Corporation